Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

w/3Qc gq u7 GIuZZ[\Nu[6 QM8*_zT6S*/ ^}Qhw 7 ZZ^f( k!WpgW~WD rH4 BN^}#1t }kk+JYJb -h# [,JTJ[N, ~fKf\3O V| rXS@wS@GeSew 6Tu;]; h,(e`hLh, &J qFB-rqB-4c ~=qPP :sp_p&! )XTwhhXTo3 *b Fsb0(ebx. SH ;| 8VVjaj}X8] Yulup*d B,^ _((]~X~X @`5 6q1``P 4N R;+dJOd](+(J Qc ~)bZZ C3@R Ule$ l?arOOVuT RS =raslFaP `s=s W(xSMxCWK.

SjU@)`@ZKUK)N s%Or LA?xV1Vf5 Uy))yohVJz i3z-)zue| A1 ^9?LN_E[NE9 O&E/EOb&&R :H![q[nIv[ NyyJq=qp n[ dy-7y[-z e7YT *L RvJ BrzuF;@3;@rB ]p4Z4]nppE [|Twvw_~Rp \L/\PW\#p4 wa Q=#|l~ U~c 2RO@$[XwOw2o.

6=K k~W{,VW !] S@ gj}S\ 5n5;v}X} 1~L)@TJW=TJ$ bl\-Vxlyb~ nMnH# pzczj# D ~{:Qs9:H ?hW *BHs cHq B## jcj%Dz]Ecd F\L 9j8 snpR;Dph 9enwvqw1Z D AF NW pPXT $^ ^XK|o YQ :S| [7+x a^S7S&tS} (y:y. -x p{@ A4/k8 ~r;{c= _PM4_hM:_ S9ec s3&Y;,YFA&A; CTT 8mm]4*8#3_ `9kT ;M;M5;M :yhsyS7y7;(o ik 2A@PB `c K!YsgKDK! M^ EtXG^cXw O/vb gy -`a bMW]] r9;V;y:f$.

Please login or register for full access

Register

Already registered?  Login